Analyst Reco. Johnson & Johnson Bulgaria S.E.

Equities

JNJ

US4781601046

End-of-day quote Bulgaria S.E. Other stock markets 06:00:00 2024-05-22 pm EDT			5-day change	1st Jan Change
140.6 ^EUR	+0.41%		+1.43%	-11.49%

May. 28	Sector Update: Health Care Stocks Fall Late Afternoon	MT
May. 28	Sector Update: Health Care Stocks Retreat Tuesday Afternoon	MT

Analyst Reco.

Unlock all the news: Be the first to know and act before the market!

100% Free Registration

Guggenheim Adjusts Johnson & Johnson's Price Target to $160 From $167	May. 01	MT
Redburn Atlantic Adjusts Johnson & Johnson Price Target to $160 From $170	Apr. 25	MT
Daiwa Securities Adjusts Johnson & Johnson's Price Target to $160 From $170, Maintains Outperform Rating	Apr. 22	MT
HSBC Upgrades Johnson & Johnson to Buy From Hold, Raises Price Target to $170 From $169	Apr. 18	MT
DZ Bank Adjusts Johnson & Johnson's Price Target to $176 From $181, Maintains Buy Rating	Apr. 18	MT
Bernstein Adjusts Johnson & Johnson's Price Target to $161 From $172, Maintains Market Perform Rating	Apr. 18	MT
BofA Securities Adjusts Price Target on Johnson & Johnson to $170 From $180, Maintains Neutral Rating	Apr. 17	MT
Morgan Stanley Adjusts Johnson & Johnson's Price Target to $167 From $168, Keeps Equalweight Rating	Apr. 17	MT
RBC Adjusts Johnson & Johnson's Price Target to $175 From $181, Keeps Outperform Rating	Apr. 17	MT
Raymond James Adjusts Johnson & Johnson's Price Target to $170 From $175, Maintains Outperform Rating	Apr. 17	MT
Stifel Cuts Johnson & Johnson's Price Target to $155 From $160	Apr. 16	MT
Morgan Stanley Trims Price Target on Johnson & Johnson to $168 From $169, Keeps Equalweight Rating	Apr. 09	MT
Johnson & Johnson Recommends Shareholders to Reject TRC Capital Investment's Mini-Tender Offer	Apr. 05	MT
J&J recommends shareholders to reject 'mini-tender' offer by TRC Capital Investment	Apr. 04	RE
Guggenheim Trims Price Target on Johnson & Johnson to $167 From $169, Maintains Neutral Rating	Jan. 24	MT
Morgan Stanley Adjusts Price Target on Johnson & Johnson to $169 From $170, Maintains Equalweight Rating	Jan. 24	MT
The market awaits the BCE meeting and earnings reports	Jan. 23
The start of a new bull market?	Jan. 22
B. Riley Downgrades Ambrx Biopharma to Neutral From Buy on Heels of Announced Sale to Johnson & Johnson, Adjusts PT to $28 From $26	Jan. 09	MT
Raymond James Raises Johnson & Johnson's Price Target to $175 From $172, Maintains Outperform Rating	Jan. 03	MT

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Headlines

Joseph Wolk, CFO of J&J: End of patent for its flagship drug

January 23, 2024 at 12:30 pm EST